W. L. Gore & Associates has received approval from the FDA to market the Gore C3 Delivery System to deploy the Gore Excluder AAA endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA).

The Gore C3 Delivery System enables physicians and interventionalists to reposition the Gore Excluder device prior to final release from the delivery catheter, according to the Flagstaff, Ariz.-based company. Once delivered into the aorta, the Gore C3 Delivery System enables repositioning of the stent graft.